

10/565717
1AP20 RECEIVED TO 23 JAN 2006

TMH/nf 01/23/06 4630-66461-04 476034 672

Express Mail No. EV668455236US
Date of Deposit: January 23, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chew *et al.*

Application No.

Filed: Herewith

Confirmation No.

For: NATURAL ASTAXANTHIN EXTRACT
REDUCES DNA OXIDATION

Examiner:

Art Unit:

Attorney Reference No. 4630-66461-04

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to the deposit account referenced in the accompanying transmittal letter.

10/565717
AP20 Rec 23 JAN 2006

Express Mail No. EV668455236US
Date of Deposit: January 23, 2006

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4630-66461-04
	Application Number	10/565717
	Filing Date	
	First Named Inventor	Chew
	Art Unit	
	Examiner Name	

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 96/13255 A (PCT/US95/14502)	05/09/1996	Board of Trustees of the University of Illinois
		Japan	JP 02049091 A	02/19/1990	Suntory Ltd

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		CHEW <i>et al.</i> , "A Comparison of the Anticancer Activities of Dietary β -Carotene, Canthaxanthin and Astaxanthin in Mice <i>in Vivo</i> ," Anticancer Research, Vol. 19, No. 3A, May 1999
		CRONIN, "The Potential of Astaxanthin: A New Multipurpose, High-Power Antioxidant," Alternative & Complementary Therapies, United States, Vol. 8, No. 1, February 2002
		GUERIN <i>et al.</i> , " <i>Haematococcus astaxanthin</i> : applications for human health and nutrition," Trends in Biotechnology, Elsevier Publications, Cambridge, United Kingdom, Vol. 21, No. 5, May 2003
		KURASHIGE <i>et al.</i> , "Inhibition of Oxidative Injury of Biological Membranes by Astaxanthin," Physiological Chemistry and Physics and Medical NMR, Vol. 22, 1990
		NISHIGAKI <i>et al.</i> , "Suppressive Effect of Astaxanthin on Lipid Peroxidation Induced in Rats," Journal of Clinical Biochemistry and Nutrition, Vol. 16, No. 3, 1994
		OHGAMI <i>et al.</i> , "Effects of Astaxanthin on Lipopolysaccharide-Induced Inflammation in Vitro and in Vivo," IOVS, Vol. 44, No. 6, June 2003
		SARRAFIZADEH <i>et al.</i> , "New therapies for the treatment of age-related macular degeneration," Expert Opinion on Therapeutic Patents, United Kingdom, Vol. 10, No. 3, 2000

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	